Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 14, 2014, Pages 1420-1428

  Belshe, Robert B ^a   Frey, Sharon E ^a   Graham, Irene L ^a   Anderson, Edwin L ^a   Jackson, Lisa A ^b   Spearman, Paul ^c   Edupuganti, Srilatha ^d   Mulligan, Mark J ^d   Rouphael, Nadine ^d   Winokur, Patricia ^e   Dolor, Rowena J ^f   Woods, Christopher W ^f   Walter, Emmanuel B ^f   Chen, Wilbur H ^g   Turley, Christine ^h   Edwards, Kathryn M ⁱ   Creech, C Buddy ⁱ   Hill, Heather ^j   Bellamy, Abbie R ^j  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c Emory Children's Center   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Maryland School of Medicine Center for Vaccine Development   (United States)

^h UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j EMMES CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA A/ANHUI/01/2005(H5N1) VACCINE; AVIAN INFLUENZA A/VIETNAM/1203/2004(H5N1) VACCINE; AVIAN INFLUENZA VACCINE; MIFAMURTIDE; PLACEBO; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INSTITUTIONAL REVIEW; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; ADOLESCENT; AGED; ANIMAL; ANTIBODY PRODUCTION; CONTROLLED CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; METHODOLOGY; MIDDLE AGED; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84907704195     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.12609     Document Type: Article

References (14)

1. US Food and Drug Administration. Sanofi pasteur influenza virus vaccine, H5N1: Full prescribing information. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM112836.pdf. Accessed June 23, 2010.
2. Department of Health and Human Services. Influenza vaccine and adjuvant stockpiles. https://www.medicalcountermeasures.gov/BARDA/documents/Day1-VCioce-InfluenzaVaccineAndAdjuvantStockpiles-508.pdf. Accessed September 16, 2014.
3. Tran TH, Nguyen TL, Nguyen TD, et al; World Health Organization International Avian Influenza Investigative Team. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004;350(12): 1179-1188.
4. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352(4):333- 340.
5. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A randomised trial of 2 potential vaccines against H5N1 influenza. Lancet. 2001;357 (9272):1937-1943.
6. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001;19(13-14):1732-1737.
7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343-1351.
8. Belshe RB, Frey SE, Graham I, et al; National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis. 2011;203(5):666-673.
9. Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol. 2009;16(4):558-566.
10. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937-943.
11. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis. 2008;197(4):580-583.
12. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3(85):85-48.
13. Tsai TF. Fluad-MF59-adjuvanted influenza vaccine in older adults. Infect Chemother. 2013;45 (2):159-174.
14. Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis. 2006;12(1):29-33.